Evaluation of treatment for diffuse large B-cell lymphoma using plasma D-dimer levels

Area of Science:

• Hematology
• Oncology
• Clinical Chemistry

Background:

• D-dimer levels are recognized for their potential role in assessing tumor activity in diffuse large B-cell lymphoma (DLBCL).
• The predictive value of D-dimer for treatment outcomes in DLBCL remains underexplored.
• This study investigates D-dimer's utility in predicting treatment efficacy for DLBCL patients.

Purpose of the Study:

• To retrospectively evaluate the role of plasma D-dimer levels in predicting treatment efficacy in patients diagnosed with DLBCL.
• To explore the correlation between D-dimer concentrations and clinical characteristics before and after chemotherapy.
• To assess D-dimer's potential as a biomarker for short-term treatment response in DLBCL.

Main Methods:

• Retrospective analysis of 151 newly diagnosed DLBCL patients.
• Measurement of plasma D-dimer levels at initial consultation and after two chemotherapy cycles.
• Exclusion of patients with coagulation disorders (DIC, DVT, PE) to minimize confounding factors.

Main Results:

• Statistically significant differences in initial D-dimer levels were observed across treatment response groups (CR, PR, SD, PD).
• Patients achieving complete response (CR) had significantly lower initial D-dimer levels and greater post-chemotherapy reductions compared to non-CR groups.
• The partial response (PR) group showed significantly lower post-chemotherapy D-dimer levels than the progressive disease (PD) group.

Conclusions:

• Plasma D-dimer levels at initial diagnosis are associated with treatment response in DLBCL.
• Changes in D-dimer levels post-chemotherapy correlate with treatment efficacy, suggesting its utility in predicting short-term response.
• Further research is needed to establish the relationship between D-dimer levels and long-term outcomes like progression-free survival (PFS) and overall survival (OS).